Key result
Astragaloside IV effectively inhibited isoprenaline-induced cardiac fibroblast proliferation and collagen production through negative regulation of ROS-mediated cardiotrophin-1 upregulation.
Why the study?
Does Astragaloside IV reduce isoprenaline-induced cardiac fibrosis in preclinical models?
Does Astragaloside IV reduce isoprenaline-induced cardiac fibrosis in preclinical models?
p-value: p=<0.05
Astragaloside IV demonstrates anti-fibrotic effects in cardiac fibroblasts by inhibiting ROS-mediated cardiotrophin-1 upregulation, suggesting a potential mechanism for preventing cardiac remodeling.
Supports mechanistic exploration of AsIV in cardiac fibrosis; leaves open any role in clinical management.
Astragaloside IV (AsIV), one of the major active ingredients in Astragalus membranaceus, has demonstrated remarkable antifibrotic effects via its antioxidative activity. Cardiac fibrosis is an important pathological mechanism during cardiac remodelling associated with heart failure. In the present study, the mechanism underlying the antifibrotic effect of AsIV upon isoprenaline (ISO) stimulation was investigated. AsIV significantly improved cardiac fibrosis in vivo and dose‑dependently inhibited ISO‑induced CF proliferation in vitro. The ISO‑triggered elevation in reactive oxygen species (ROS) levels was remarkably inhibited by AsIV, as well as ROS scavenger N‑acetylcysteine (NAC), and not affected by cardiotrophin‑1 (CT‑1) knockdown. In addition, AsIV effectively reversed ISO‑induced upregulation of CT‑1 expression, which was blunted by pretreatment with NAC. Cardiac fibroblast (CF) proliferation and collagen Ι overexpression induced by ISO stimulation were effectively abrogated by AsIV, NAC, and CT‑1 small interfering RNA transfection. Taken together, these results demonstrated that AsIV was able to effectively inhibit ISO‑induced CF proliferation and collagen production through negative regulation of ROS‑mediated CT‑1 upregulation.
No takes yet. Share an insight, caveat, or question.
Jia et al. (2017) studied Cardiac fibrosis (n=30). Astragaloside IV vs. Isoprenaline alone or vehicle control was evaluated on Cardiac fibroblast proliferation and collagen production (p=<0.05). Astragaloside IV effectively inhibited isoprenaline-induced cardiac fibroblast proliferation and collagen production through negative regulation of ROS-mediated cardiotrophin-1 upregulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: